Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers

被引:54
作者
Tada, Toshifumi [1 ]
Kumada, Takashi [1 ]
Toyoda, Hidenori [1 ]
Kobayashi, Natsuko [1 ]
Akita, Tomoyuki [2 ]
Tanaka, Junko [2 ]
机构
[1] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, 4-86 Minaminokawa, Ogaki, Gifu 5038502, Japan
[2] Hiroshima Univ, Dept Epidemiol Infect Dis Control & Prevent, Inst Biomed & Hlth Sci, Hiroshima, Hiroshima, Japan
关键词
Fibrosis-4; index; hepatitis B; hepatitis B virus core-related antigen; liver cirrhosis; NUCLEOS(T)IDE ANALOG THERAPY; SIMPLE NONINVASIVE INDEX; HEPATOCELLULAR-CARCINOMA; SIGNIFICANT FIBROSIS; ENZYME-IMMUNOASSAY; SURFACE-ANTIGEN; EPIDEMIOLOGY; CESSATION; MARKERS; BIOPSY;
D O I
10.1111/jgh.13989
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimSeveral hepatitis B virus (HBV) markers have been identified as risk factors for progression to liver cirrhosis in patients with chronic HBV infection. The predictive impact of HBV markers on progression to cirrhosis in HBV carriers was clarified. MethodsA total of 529 hepatitis B e antigen seroconverters with fibrosis-4 (FIB-4) index 3.6 not on nucleos(t)ide analogue therapy were included. Univariate and multivariate analyses of associations between HBV markers and progression to cirrhosis were performed. In addition, the hazard ratio (HR) spline curves for continuous HBV markers were compared. ResultsEighty-four patients progressed to cirrhosis (FIB-4 index >3.6) during the follow-up period. Hepatitis B surface antigen (HBsAg), HBV DNA, HBV core-related antigen (HBcrAg), and basal core promoter status, but not genotype and precore status, were significantly associated with progression to cirrhosis in univariate Cox proportional hazards models. Multivariate Cox proportional hazards models adjusted for HBV genotype, HBsAg, HBV DNA, HBcrAg, precore status, and basal core promoter status indicated that HBsAg 3.0logIU/mL (HR, 0.53; 95% confidence interval [CI], 0.30-0.94) and HBcrAg 3.7logU/mL (HR, 3.28; 95% CI, 1.60-6.75) are independently associated with progression to cirrhosis. In the HR spline curve analysis, HR and 95% CI gradually increased as HBcrAg levels increased. Conversely, HRs and 95% CIs for HBsAg and HBV DNA did not show this tendency as their levels increased. ConclusionsElevated HBcrAg levels in HBV carriers increases the risk for progression to cirrhosis. HBcrAg is an excellent predictor of the development of cirrhosis.
引用
收藏
页码:918 / 925
页数:8
相关论文
共 44 条
[2]  
BEASLEY RP, 1981, LANCET, V2, P1129
[3]   Current concepts: Liver biopsy. [J].
Bravo, AA ;
Sheth, SG ;
Chopra, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :495-500
[4]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[5]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[6]   Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model [J].
Forns, X ;
Ampurdanès, S ;
Llovet, JM ;
Aponte, J ;
Quintó, L ;
Martínez-Bauer, E ;
Bruguera, M ;
Sánchez-Tapias, JM ;
Rodés, J .
HEPATOLOGY, 2002, 36 (04) :986-992
[7]   Role of liver biopsy in management of chronic hepatitis C: A systematic review [J].
Gebo, KA ;
Herlong, HF ;
Torbenson, MS ;
Jenckes, MW ;
Chander, G ;
Ghanem, KG ;
El-Kamary, SS ;
Sulkowski, M ;
Bass, EB .
HEPATOLOGY, 2002, 36 (05) :S161-S172
[8]   Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma [J].
Honda, Masao ;
Shirasaki, Takayoshi ;
Terashima, Takeshi ;
Kawaguchi, Kazunori ;
Nakamura, Mikiko ;
Oishi, Naoki ;
Wang, Xuyang ;
Shimakami, Tetsuro ;
Okada, Hikari ;
Arai, Kuniaki ;
Yamashita, Taro ;
Sakai, Yoshio ;
Yamashita, Tatsuya ;
Mizukoshi, Eishiro ;
Kaneko, Shuichi .
JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (07) :1096-1106
[9]   Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection [J].
Hosaka, Tetsuya ;
Suzuki, Fumitaka ;
Kobayashi, Masahiro ;
Seko, Yuya ;
Kawamura, Yusuke ;
Sezaki, Hitomi ;
Akuta, Norio ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
HEPATOLOGY, 2013, 58 (01) :98-107
[10]   HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy [J].
Hosaka, Tetsuya ;
Suzuki, Fumitaka ;
Kobayashi, Masahiro ;
Hirakawa, Miharu ;
Kawamura, Yusuke ;
Yatsuji, Hiromi ;
Sezaki, Hitomi ;
Akuta, Norio ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
LIVER INTERNATIONAL, 2010, 30 (10) :1461-1470